KRAS and ovarian serous carcinoma: To address this need, we generated a new panel of comprehensively characterized models which are highly representative of clinical HGSOC tumors with the exception of one case (HCC5075 was TP53 wild-type, KRAS mutant, and had low genomic instability which are features are consistent with low-grade serous ovarian carcinoma [14, 25, 27, 34, 35]).